Catalyst Pharmaceuticals achieved record revenues in Q4 2025, reaching $152.6 million, a 7.6% increase year-over-year. Growth was primarily driven by FIRDAPSE and the continued market uptake of AGAMREE, despite the entry of generic competitors for FYCOMPA. The company ended the year with a strong cash position of $709.2 million and provided optimistic 2026 guidance.

Catalyst Pharmaceuticals achieved total revenues of $148.4 million in Q3 2025, a 17.4% increase year-over-year, primarily due to robust sales of FIRDAPSE and AGAMREE. The company also raised its full-year 2025 total revenue guidance, reflecting confidence in its growth trajectory.

Catalyst Pharmaceuticals achieved record total revenues in Q2 2025, reaching $146.6 million, a 19.4% increase year-over-year. This growth was primarily fueled by strong performances from FIRDAPSE and AGAMREE, with AGAMREE showing exceptional triple-digit growth. The company also maintained a strong cash position with $652.8 million and no funded debt.

Catalyst Pharmaceuticals delivered record first quarter 2025 total revenues of $141.4 million, a 43.6% year-over-year increase, driven by strong performance from FIRDAPSE and AGAMREE. The company ended the quarter with a strong balance sheet, including $580.7 million in cash and cash equivalents and no debt.

Catalyst Pharmaceuticals achieved record fourth quarter and full year 2024 financial results, with total revenues reaching $141.8 million for Q4 and $491.7 million for the full year, driven by sustained organic growth of FIRDAPSE and the successful market adoption of AGAMREE.